FDA Approves First GLP-1 Generic for Weight Loss

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceuticals’ generic version of Novo Nordisk’s Saxenda (liraglutide), a first-generation glucagon-like peptide-1 (GLP-1) receptor agonist. The generic is approved to treat adults and adolescents 12 to 17 years of age who are obese or overweight. This is the first time a generic glucagon-like peptide-1 receptor agonist (GLP-1RA) medication has been approved for weight loss in the US.

Read more at Reuters >>